ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC

Bookmark and Share
Published: 14 Sep 2022
Views: 72
Rating:
Save
Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy

Dr Armando Orlandi speaks to ecancer about ERMES, a phase III study which looked at FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab alone in first-line therapy of RAS and BRAF wild-type metastatic colorectal cancer patients.

The ERMES study results did not demonstrate non-inferiority of maintenance with cetuximab alone. The higher-than-expected drop-out rate and subsequent reduced statistical power might have impaired the results. The ITT analysis and overall survival results are suggestive for a strategy of de-escalation treatment with only cetuximab. 

Ongoing translational analyses might allow to select patients benefitting from de-escalation strategy.

ERMES study does not demonstrate non-inferiority of maintenance